Shares of Moderna (NASDAQ: MRNA) jumped 8.6% on Monday after the biotechnology leader said it dosed the first participant in a new clinical trial for its experimental vaccine for human immunodeficiency virus (HIV).
The phase 1 study is designed to evaluate the vaccine's safety profile and ability to provoke an immune response in approximately 100 adults aged 18 to 55 years who are HIV negative. The National Institutes of Health (NIH) is helping to fund the trial.
Image source: Getty Images.
Source Fool.com